Highlights from the interview in the LSR:

TSLR: How does a company of this size perform a Phase 3 trial of this magnitude with no partner?

MW: Cash on the balance sheet is roughly CA$40M, which is obviously not enough to do the whole trial. Resverlogix definitely needs a partnership with a larger company. Resverlogix's strategy is to make a few regional partnerships. It has already partnered with Shenzhen Hepalink Pharmaceutical Co. Ltd. (002399:SHE) for a license on RVX-208 in China, Hong Kong, Taiwan and Macau. The agreement gave Resverlogix cash to start the Phase 3 trial. I think Resverlogix's strategy is to start with the clinical trial, derive data, and create value to increase the likelihood of a partnership deal with a large pharmaceutical company. I would also mention that the company has quite a lot of data from previous trials that it can use.

TLSR: Do you imagine the interim data could drive a partnership?

MW: Absolutely. I think it's very important for a potential partner to see preliminary signs of efficacy and larger-scale safety data. A substantial deal could be struck. One of the potential partners could be AstraZeneca.